ARCHIVE SEARCH
      -OR-  
 
  NEWS CHANNELS
Fitness News
Asthma Allergy News
 > Diabetes News
Women's Health News
Men's Health News

  MY NEWS
Personal Archive
My Account

  ABOUT THIS NEWSFEED
About Us
Advertise With Us
Feed Your Site
Contact Us


Site Map
RSS News Feed 

  Website development & hosting
   by Cyber Software Solutions

 
Antiviral Treatment Benefits Patients With Diabetes
HCV treatment may lower risk of end-stage renal disease, stroke, acute coronary syndrome

THURSDAY, Dec. 19, 2013 (HealthDay News) -- Patients with diabetes have a lower risk of end-stage renal disease, stroke, and acute coronary syndrome after antiviral treatment for hepatitis C virus (HCV), according to a study published online in Hepatology.

Noting that HCV infection has been linked to diabetes mellitus and insulin resistance, Yao-Chun Hsu, Ph.D., from the China Medical University in Taichung, Taiwan, and colleagues studied 2,822 patients with diabetes mellitus but without serious comorbidities, where half were untreated and half were treated with pegylated interferon plus ribavirin. The treated group was also matched with 5,644 patients with diabetes without HCV infection.

After eight years, the researchers found that the cumulative incidence of end-stage renal disease, ischemic stroke, and acute coronary syndrome varied significantly between groups. Compared with the untreated group, and after adjusting for various factors, the treated group had a significantly lower risk of end-stage renal disease (hazard ratio [HR], 0.16), ischemic stroke (HR, 0.53), and acute coronary syndrome (HR, 0.64).

"Antiviral treatment for HCV infection is associated with improved renal and cardiovascular outcomes in diabetic patients," Hsu and colleagues conclude.

One author disclosed receiving lecture fees from Merck Sharp & Dohme and Roche.

Abstract
Full Text (subscription or payment may be required)



Copyright © 2013 HealthDay. All rights reserved.


Back to Top Stories
  GOOGLE ADS